New combo aims to keep advanced colon cancer in check

NCT ID NCT05775900

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small, early-phase trial tested a combination of two drugs—cetuximab and capecitabine—as a maintenance treatment for people with a specific genetic type of advanced colorectal cancer (KRAS/BRAF wild-type). The main goals were to check safety, find the best dose, and see how the drugs move through the body. Only 24 people took part, so the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cetuximab (Erbitux) and capecitabine
What this could lead to: If successful, this could offer a more convenient maintenance treatment option for people with a specific type of advanced colorectal cancer.
What could go wrong: This is a very small, early-phase trial (24 people) that only looked at safety and dosing, not whether the treatment actually works. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Locations

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.